# A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07699328/  
OnCo record `nct07699328` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VRN110755 in non-small-cell lung cancer and small-cell lung cancer, run by Voronoi, Inc, now recruiting.

## Summary

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07699328 by Voronoi, Inc, with 315 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-01-01. Interventions recorded: VRN110755. Conditions listed: EGFR-Mutant Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07699328
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Voronoi, Inc
- Enrolled: 315

## Sources

- ClinicalTrials.gov NCT07699328: https://clinicaltrials.gov/study/NCT07699328

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [VRN110755](https://onco.cc/drugs/vrn110755/)

---
JSON: https://onco.cc/api/v1/entities/nct07699328.json